1
|
Masterson JC, McNamee EN, Hosford L, Capocelli KE, Ruybal J, Fillon SA, Doyle AD, Eltzschig HK, Rustgi AK, Protheroe CA, Lee NA, Lee JJ, Furuta GT. Local hypersensitivity reaction in transgenic mice with squamous epithelial IL-5 overexpression provides a novel model of eosinophilic oesophagitis. Gut 2014; 63:43-53. [PMID: 23161496 PMCID: PMC3884674 DOI: 10.1136/gutjnl-2012-303631] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE Eosinophilic oesophagitis (EoE) is a chronic inflammatory condition of the oesophagus with limited treatment options. No previous transgenic model has specifically targeted the oesophageal mucosa to induce oesophageal eosinophilia. DESIGN We developed a mouse model that closely resembles EoE by utilising oxazolone haptenation in mice with transgenic overexpression of an eosinophil poietic and survival factor (interleukin (IL)-5) in resident squamous oesophageal epithelia. RESULTS Overexpression of IL-5 in the healthy oesophagus was achieved in transgenic mice (L2-IL5) using the squamous epithelial promoter Epstein-Barr virus ED-L2. Oxazolone-challenged L2-IL5 mice developed dose-dependent pan-oesophageal eosinophilia, including eosinophil microabscess formation and degranulation as well as basal cell hyperplasia. Moreover, oesophagi expressed increased IL-13 and the eosinophil agonist chemokine eotaxin-1. Treatment of these mice with corticosteroids significantly reduced eosinophilia and epithelial inflammation. CONCLUSIONS L2-IL5 mice provide a novel experimental model that can potentially be used in preclinical testing of EoE-related therapeutics and mechanistic studies identifying pathogenetic features associated with mucosal eosinophilia.
Collapse
Affiliation(s)
- Joanne C Masterson
- Section of Pediatric Gastroenterology, Hepatology and Nutrition, Digestive Health Institute, Aurora, Colorado, USA,Gastrointestinal Eosinophilic Diseases Program, Aurora, Colorado, USA,Children’s Hospital Colorado, Aurora, Colorado, USA,Mucosal Inflammation Program, University of Colorado Denver, Aurora, Colorado, USA,University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| | - Eóin N McNamee
- Mucosal Inflammation Program, University of Colorado Denver, Aurora, Colorado, USA,Department of Anesthesiology, University of Colorado Denver, Aurora, Colorado, USA,University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| | - Lindsay Hosford
- Section of Pediatric Gastroenterology, Hepatology and Nutrition, Digestive Health Institute, Aurora, Colorado, USA,Gastrointestinal Eosinophilic Diseases Program, Aurora, Colorado, USA,Children’s Hospital Colorado, Aurora, Colorado, USA,Mucosal Inflammation Program, University of Colorado Denver, Aurora, Colorado, USA,University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| | - Kelley E Capocelli
- Gastrointestinal Eosinophilic Diseases Program, Aurora, Colorado, USA,Children’s Hospital Colorado, Aurora, Colorado, USA,Department of Pathology, Children’s Hospital Colorado, Aurora, Colorado, USA,University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| | - Joseph Ruybal
- Section of Pediatric Gastroenterology, Hepatology and Nutrition, Digestive Health Institute, Aurora, Colorado, USA,Gastrointestinal Eosinophilic Diseases Program, Aurora, Colorado, USA,Children’s Hospital Colorado, Aurora, Colorado, USA,Mucosal Inflammation Program, University of Colorado Denver, Aurora, Colorado, USA,University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| | - Sophie A Fillon
- Section of Pediatric Gastroenterology, Hepatology and Nutrition, Digestive Health Institute, Aurora, Colorado, USA,Gastrointestinal Eosinophilic Diseases Program, Aurora, Colorado, USA,Children’s Hospital Colorado, Aurora, Colorado, USA,Mucosal Inflammation Program, University of Colorado Denver, Aurora, Colorado, USA,University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| | - Alfred D Doyle
- Department of Biochemistry and Molecular Biology, Mayo Clinic Scottsdale, Arizona, USA
| | - Holger K Eltzschig
- Mucosal Inflammation Program, University of Colorado Denver, Aurora, Colorado, USA,Department of Anesthesiology, University of Colorado Denver, Aurora, Colorado, USA,University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| | - Anil K Rustgi
- Division of Gastroenterology, Department of Medicine and Genetics, University of Pennsylvania, Philadelphia, USA
| | - Cheryl A Protheroe
- Department of Biochemistry and Molecular Biology, Mayo Clinic Scottsdale, Arizona, USA
| | - Nancy A Lee
- Department of Biochemistry and Molecular Biology, Mayo Clinic Scottsdale, Arizona, USA
| | - James J Lee
- Department of Biochemistry and Molecular Biology, Mayo Clinic Scottsdale, Arizona, USA
| | - Glenn T Furuta
- Section of Pediatric Gastroenterology, Hepatology and Nutrition, Digestive Health Institute, Aurora, Colorado, USA,Gastrointestinal Eosinophilic Diseases Program, Aurora, Colorado, USA,Children’s Hospital Colorado, Aurora, Colorado, USA,Mucosal Inflammation Program, University of Colorado Denver, Aurora, Colorado, USA,University of Colorado Denver School of Medicine, Aurora, Colorado, USA
| |
Collapse
|